Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.
about
Receptor for advanced glycation end products and its involvement in inflammatory diseasesChemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE)Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic miceHyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylationHow hyperglycemia promotes atherosclerosis: molecular mechanisms.Large animal models of cardiovascular diseaseAdvanced Glycation End Products: Link between Diet and Ovulatory Dysfunction in PCOS?Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary SyndromeCurrent perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary managementMolecular Pathways Regulating Macrovascular Pathology and Vascular Smooth Muscle Cells Phenotype in Type 2 DiabetesAnimal models of diabetic macrovascular complications: key players in the development of new therapeutic approachesInsulin resistance, hyperglycemia, and atherosclerosisRAGE: a new frontier in chronic airways diseaseInhibition of nuclear factor of activated T-cells (NFAT) suppresses accelerated atherosclerosis in diabetic miceSoluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice.Structural Basis for Ligand Recognition and Activation of RAGEStable RAGE-Heparan Sulfate Complexes Are Essential for Signal TransductionMolecular Imaging of Vulnerable Atherosclerotic Plaques in Animal Models.Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting proteinDevelopment and prevention of advanced diabetic nephropathy in RAGE-overexpressing miceHyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine modelPPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null miceRAGE mediates accelerated diabetic vein graft atherosclerosis induced by combined mechanical stress and AGEs via synergistic ERK activationA role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosisPurification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE)The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cellsIdentification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expressionThe multiple faces of RAGE--opportunities for therapeutic intervention in aging and chronic diseasePlasma Soluble Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis.Pimagedine: a novel therapy for diabetic nephropathy.Intraoperative sRAGE kinetics. A new age-related outcome predictor of cardiac surgery.[Protein glycation as a pathological mechanism in diabetes].Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia.Diabetic conditions promote binding of monocytes to vascular smooth muscle cells and their subsequent differentiationVascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- miceAdvanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathwayFEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products.O-glycosylation regulates ubiquitination and degradation of the anti-inflammatory protein A20 to accelerate atherosclerosis in diabetic ApoE-null mice.
P2860
Q21285070-E2FBBFED-F893-49B7-8B8C-00DFB0AA4828Q24310573-DA00F47B-CECD-40B2-90B1-259B346AEF39Q24323192-D46BB089-03A5-4EC0-B38F-D974A3261B7DQ24337632-7AA5DA06-3CBD-4366-8D56-0480B9FCEEB2Q24530027-65D405A1-A0D2-4956-8E18-BED04BB27F0FQ24682735-FB7D869B-E774-413C-9811-9E7D5C8ECF74Q24795988-C014C5C3-6A8A-4D03-ACD1-13537D2392C1Q26766350-8B879DEF-2AE0-487A-82C4-7CFB90005F33Q26774333-EE07595B-2F99-4E98-969A-4BDF9466F0C1Q26780488-AC9241E3-22D0-4B90-9CFC-4C13C60308E4Q26781156-03E31C3A-A717-4C99-950D-DF367056F5E0Q26782445-E9F9F93D-277B-4E8C-9A40-5BFEB912083BQ26822630-B97D8FDF-A80E-45AE-BAFB-4A63654AFFF4Q27011696-9467C328-FA49-4ACD-A29F-18A45E4FFDB8Q27025295-EE949900-C082-4239-A91B-0F22C38D6087Q27317653-96DE1A38-AB97-4A46-A65A-48926713F169Q27319831-59E6166F-04B0-4691-99F5-80951776456BQ27665039-88657E9C-C030-465E-8EDB-DCEBC495AFC0Q27678167-F31BEB72-760E-477E-9D0C-0E618837774AQ28070313-57991F75-A29A-4D6B-A03A-85EA2A0DE23DQ28260396-F3FF18BC-EC29-4474-A1B8-0BF1FDA77A5AQ28344139-4ABF6B25-15B7-426A-8534-7DFA04DAB876Q28360470-C857157C-48CC-46FC-90FD-8BB99DB69DD7Q28362804-8A936EA1-A3A6-4757-BB58-A243070460F2Q28482199-2A52EFAE-968B-445C-9749-984AA064550DQ28507626-7344B3BF-F08F-4953-B3BA-4964DB06A4B0Q28508886-3F9E111F-8756-456D-9A79-CFAFEAF0FA5CQ28570659-E724AB0F-B19B-4ED5-BF2B-614AC29C0A95Q28590453-684F4EFE-E72F-47C2-BBF0-B15AD3617D33Q28830568-C473DEB4-47B4-4EF9-A32B-E3FDD36C4133Q30253065-4204F3EA-88EE-4371-854A-8AECD80B9408Q30309168-E2AC808D-C0EB-4255-82A6-93CE9703A5F6Q30317651-E0C6B9F2-2ED8-4D50-BAB0-88AD99D4A766Q30318169-7DC50F6C-71DD-44A9-A246-BCFD5710E7D4Q30378823-4944899F-D308-49F5-AA56-7040AA9E9DBBQ30433016-C95FA459-F29E-49B7-80A2-67A1D4A96B80Q30444108-6C0405C2-6231-4D49-A51C-BC3603214531Q30445160-8366B409-4BCC-49DF-A2AF-B32DDEBCCCE3Q30873486-4F95786B-C0D6-4865-9864-6C0E030A540FQ30993051-3409B0CD-D281-49DD-AF0C-37F6A28E12B8
P2860
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Suppression of accelerated dia ...... dvanced glycation endproducts.
@en
type
label
Suppression of accelerated dia ...... dvanced glycation endproducts.
@en
prefLabel
Suppression of accelerated dia ...... dvanced glycation endproducts.
@en
P2093
P356
P1433
P1476
Suppression of accelerated dia ...... dvanced glycation endproducts.
@en
P2093
Ferran LJ Jr
Schmidt AM
P2888
P304
P356
10.1038/2012
P407
P577
1998-09-01T00:00:00Z